[HAART and changes of epidemiology, treatment and prognosis of HIV-positive patients with Kaposi's sarcoma and lymphoma].
Highly active antiretroviral therapy (HAART) has changed the epidemiology of Kaposi's sarcoma (KS) and lymphoma occurring in people living with HIV. The KS's decrease was observed early after HAART availability: although delayed, the decrease of non Hodgkin lymphoma has been sign. The improvement of immune status due to HAART has decreased the occurrence of chemotherapy triggered opportunistic infections, and survival rates have been improved. The administration of chemotherapy with HAART does not seem to increase toxicity.
Gabarre
Jean
J
Services d'hématologie clinique et des maladies infectieuses et tropicales, hôpital Pitié-Salpêtrière, 47, boulevard de l'Hôpital, 75013 Paris.
Bossi
Philippe
P
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy / Q000453:epidemiology* / Q000821:virology*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000453:epidemiology* / Q000821:virology*; D011379:Prognosis; D012514:Sarcoma, Kaposi / Q000188:drug therapy / Q000453:epidemiology* / Q000821:virology*; D013534:Survival